Boehringer Ingelheim Acquires Cancer Immunotherapy Developer Abexxa Biologics

Boehringer Ingelheim is expanding into cancer immunotherapies through its purchase of Texas-based drugmaker Abexxa Biologics for an undisclosed amount.

The deal will give Boehringer access to Abexxa’s technology for developing precision medicines that target cancer-specific proteins found inside cells, rather than those expressed on the cell membrane, an approach taken by other therapies.

The companies said their method enlarges the number of possible antigen targets, which could lead to cancer immunotherapies for a broader range of patients and cancer types.